Jules Bordet Institute registers Phase 2 scalp cooling trial for ADC-related hair lossNov 16Trial updateGilead Sciencessacituzumab govitecan
FDA accelerated approval for Enhertu in HER2-positive solid tumors, dated April 5, 2024Nov 9Regulatory decisionAmgenDaiichi Sankyo
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
Enhertu wins EU approval for adjuvant HER2-positive early breast cancerOct 27Regulatory decisionAstraZenecaDaiichi Sankyo
Daiichi Sankyo registers Phase 3b T-DXd sequencing trial; posts RWE and access-program studiesOct 16Weekly roundup, 3 itemsAstraZenecaDaiichi Sankyo
AstraZeneca, Daiichi Sankyo, Summit to test Datroway with ivonescimab comboOct 2PartnershipAstraZenecaDaiichi Sankyo
CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
EU clears Enhertu plus pertuzumab as first-line HER2-positive metastatic breast cancer therapyAug 31Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readoutAug 6Quarterly updateALX Oncology Inc.
Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trialsJul 17Weekly roundup, 8 itemsbelzutifanDaiichi Sankyo
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
EU approves Enhertu as first tumor-agnostic HER2-directed ADCJun 29Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki